Table 2.
Histopathology and comorbidities stratified by fatigue*
| Total (N = 160) | Mild (n = 43) | Moderate (n = 60) | Severe (n = 49) | P value | |
|---|---|---|---|---|---|
| Synovial lymphocytic inflammation | 0.36 | ||||
| None | 29 (18.1) | 11 (25.0) | 10 (15.6) | 8 (15.4) | |
| Mild | 50 (31.2) | 17 (38.6) | 20 (31.2) | 13 (25.0) | |
| Moderate | 35 (21.9) | 6 (13.6) | 13 (20.3) | 16 (30.8) | |
| Marked | 28 (17.5) | 7 (15.9) | 14 (21.9) | 7 (13.5) | |
| Band‐like | 18 (11.2) | 3 (6.8) | 7 (10.9) | 8 (15.4) | |
| Plasma cell inflammation | 0.34 | ||||
| <10% | 98 (61.3) | 30 (68.2) | 38 (59.4) | 30 (57.7) | |
| <50% | 28 (17.5) | 4 (9.1) | 15 (23.4) | 9 (17.3) | |
| >50% | 34 (21.2) | 10 (22.7) | 11 (17.2) | 13 (25.0) | |
| Synovial lining hyperplasia | 0.06 | ||||
| Normal | 5 (3.1) | 4 (9.1) | 0 (0.0) | 1 (1.9) | |
| 1–3 cells | 72 (45.0) | 21 (47.7) | 33 (51.6) | 18 (34.6) | |
| 3–4 cells | 43 (26.9) | 12 (27.3) | 16 (25.0) | 15 (28.8) | |
| >4 cells | 40 (25.0) | 7 (15.9) | 15 (23.4) | 18 (34.6) | |
| Fibrin | 71 (44.4) | 15 (34.1) | 31 (48.4) | 25 (48.1) | 0.28 |
| Binucleate plasma cells | 44 (27.5) | 10 (22.7) | 17 (26.6) | 17 (32.7) | 0.56 |
| Giant cells | 21 (13.8) | 9 (20.5) | 10 (15.6) | 5 (9.6) | 0.32 |
| History of back pain | 47 (29.4) | 6 (13.6) | 18 (28.1) | 23 (44.2) | 0.004 |
| History of FM | 7 (4.4) | 2 (4.5) | 2 (3.1) | 3 (5.8) | 0.89 |
| History of MACE | 23 (14.4) | 8 (18.2) | 8 (12.5) | 7 (13.5) | 0.66 |
| History of anemia/ blood disease | 85 (53.1) | 21 (47.7) | 33 (51.6) | 31 (59.6) | 0.51 |
| History of DVT/PE/VTE | 4 (2.5) | 2 (4.5) | 1 (1.6) | 1 (1.9) | 0.68 |
| History of pulmonary disease | 19 (11.9) | 6 (13.6) | 6 (9.4) | 7 (13.5) | 0.71 |
| History of thyroid disease | 22 (13.8) | 5 (11.4) | 7 (10.9) | 10 (19.2) | 0.43 |
| History of mental illness | 30 (18.8) | 8 (18.2) | 9 (14.1) | 13 (25.0) | 0.32 |
| History of osteoporosis | 15 (9.4) | 4 (9.1) | 5 (7.8) | 6 (11.5) | 0.75 |
| History of cancer | 18 (11.2) | 7 (15.9) | 6 (9.4) | 5 (9.6) | 0.54 |
Note: Bolded values significant P < 0.05.
*
Source: Data are presented as n (%).
DVT, deep vein thrombosis; FM, fibromyalgia; MACE, major acute cardiac events; PE, pulmonary embolism; VTE, venous thromboembolism.